Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 538

1.

Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds.

Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S.

Breast Cancer Res. 2018 Jun 8;20(1):49. doi: 10.1186/s13058-018-0979-x.

2.

Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively.

Ahmad AS, Parameshwaran V, Beltran L, Fisher G, North BV, Greenberg D, Soosay G, Møller H, Scardino P, Cuzick J, Berney DM; Transatlantic Prostate Group.

Oncotarget. 2018 Apr 17;9(29):20555-20562. doi: 10.18632/oncotarget.24994. eCollection 2018 Apr 17.

3.

Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.

Hackett J, Thorneloe R, Side L, Wolf M, Horne R, Cuzick J, Smith SG.

Breast Cancer Res Treat. 2018 Apr 24. doi: 10.1007/s10549-018-4775-1. [Epub ahead of print]

PMID:
29687178
4.

Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.

Cuzick J.

Br J Cancer. 2018 May;118(9):1155-1161. doi: 10.1038/s41416-018-0039-4. Epub 2018 Apr 23. Review.

PMID:
29681616
5.

Molecular progression to cervical precancer, epigenetic switch or sequential model?

Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, Boer S, Cuzick J, Lorincz A.

Int J Cancer. 2018 Apr 21. doi: 10.1002/ijc.31549. [Epub ahead of print]

PMID:
29679470
6.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J.

J Clin Oncol. 2018 Apr 20:JCO2017764258. doi: 10.1200/JCO.2017.76.4258. [Epub ahead of print]

PMID:
29676944
7.

Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.

Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J.

Urol Oncol. 2018 Jun;36(6):310.e7-310.e13. doi: 10.1016/j.urolonc.2018.03.011. Epub 2018 Apr 11.

PMID:
29655620
8.

Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density.

Brentnall AR, Cuzick J, Buist DSM, Bowles EJA.

JAMA Oncol. 2018 Apr 5:e180174. doi: 10.1001/jamaoncol.2018.0174. [Epub ahead of print]

PMID:
29621362
9.

Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.

Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, Frayle H, Trevisan M, Sani C, Burroni E, Giorgi Rossi P, Cuzick J, Ronco G; New Technologies for Cervical CancerWorking Group.

Int J Cancer. 2018 Jul 15;143(2):333-342. doi: 10.1002/ijc.31326. Epub 2018 Mar 9.

PMID:
29453769
10.

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, Ferree S, Sgroi D, Schnabel C, Baehner FL, Mallon E, Dowsett M.

JAMA Oncol. 2018 Apr 1;4(4):545-553. doi: 10.1001/jamaoncol.2017.5524.

11.

A comparison of five methods of measuring mammographic density: a case-control study.

Astley SM, Harkness EF, Sergeant JC, Warwick J, Stavrinos P, Warren R, Wilson M, Beetles U, Gadde S, Lim Y, Jain A, Bundred S, Barr N, Reece V, Brentnall AR, Cuzick J, Howell T, Evans DG.

Breast Cancer Res. 2018 Feb 5;20(1):10. doi: 10.1186/s13058-018-0932-z.

12.

Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK.

Evans DG, Brentnall AR, Harvie M, Astley S, Harkness EF, Stavrinos P, Donnelly LS, Sampson S, Idries F, Watterson D, Cuzick J, Wilson M, Jain A, Harrison F, Maxwell AJ, Howell A.

BMC Public Health. 2018 Jan 25;18(1):178. doi: 10.1186/s12889-018-5090-9.

13.

The Value of Helicobacter Eradication in Long-term Aspirin Users.

Cuzick J.

J Natl Cancer Inst. 2018 Jan 19. doi: 10.1093/jnci/djx289. [Epub ahead of print] No abstract available.

PMID:
29361008
14.

Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction.

van Veen EM, Brentnall AR, Byers H, Harkness EF, Astley SM, Sampson S, Howell A, Newman WG, Cuzick J, Evans DGR.

JAMA Oncol. 2018 Apr 1;4(4):476-482. doi: 10.1001/jamaoncol.2017.4881.

PMID:
29346471
15.

SNPs for breast cancer risk assessment.

Cuzick J, Brentnall A, Dowsett M.

Oncotarget. 2017 Nov 3;8(59):99211-99212. doi: 10.18632/oncotarget.22278. eCollection 2017 Nov 21. No abstract available.

16.

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.

Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J.

Ann Oncol. 2018 Feb 1;29(2):504-509. doi: 10.1093/annonc/mdx713.

17.

RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.

Howell A, Ashcroft L, Fallowfield L, Eccles DM, Eeles RA, Ward A, Brentnall AR, Dowsett M, Cuzick JM, Greenhalgh R, Boggis C, Motion J, Sergeant JC, Adams J, Evans DG.

Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):58-66. doi: 10.1158/1055-9965.EPI-17-0158. Epub 2017 Nov 2.

PMID:
29097444
18.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Papillomavirus Res. 2016 Dec;2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

19.

Need for expanded HPV genotyping for cervical screening.

Cuzick J, Wheeler C.

Papillomavirus Res. 2016 Dec;2:112-115. doi: 10.1016/j.pvr.2016.05.004. Epub 2016 Jun 1.

20.

A novel and fully automated mammographic texture analysis for risk prediction: results from two case-control studies.

Wang C, Brentnall AR, Cuzick J, Harkness EF, Evans DG, Astley S.

Breast Cancer Res. 2017 Oct 18;19(1):114. doi: 10.1186/s13058-017-0906-6.

Supplemental Content

Loading ...
Support Center